Aster DM NCLT order clears Quality Care merger in 2026

NCLT approval is in, but the merger is not yet effective

Aster DM Healthcare said it has received the National Company Law Tribunal (NCLT) order approving the Scheme of Amalgamation of Quality Care India Limited (QCIL) into Aster DM Healthcare Limited. The order was passed by the NCLT Hyderabad Bench, and the company also noted receipt of a certified true copy. This approval is a key legal milestone because it sanctions the scheme under the Companies Act framework used for court-approved mergers.

But the company also clarified an important distinction for investors: the amalgamation is approved, yet it is not “effective” at this stage. The scheme becomes effective only after the NCLT order is filed with the Registrar of Companies (RoC) and other conditions in the scheme are satisfied. Until that happens, QCIL will continue to exist as a separate entity.

What Aster DM disclosed about the order dates

The disclosures referenced two dates tied to the NCLT process. One part of the information states the certified true copy was received for an NCLT Hyderabad Bench order dated 23 June 2026. Another exchange-filing summary cited an order dated 19 June 2026 that sanctioned the scheme under Sections 230 to 232 of the Companies Act, 2013.

For investors tracking statutory progress, the practical takeaway remains the same in both descriptions: the merger’s legal sanction has been obtained and the remaining step is completion of post-order filings and conditions. The effective date will be announced by the company after the scheme becomes effective.

The remaining step: filing with the Registrar of Companies

Aster DM stated the scheme will formally come into effect upon filing the certified copy of the NCLT order with the RoC by the respective entities and fulfilling other conditions specified in the scheme. This is the point at which the amalgamation moves from “approved” to “effective” in corporate law terms.

The company indicated it will announce the effective date to the stock exchanges after completion. Investors were also advised to monitor for the company’s announcement confirming the RoC filing, since that filing is expected to mark completion. Upon effectiveness, QCIL will stand dissolved without winding up, as per the scheme description.

What happens to QCIL until the effective date

Aster DM’s update explicitly states that until the scheme becomes effective, Quality Care India Limited will continue to exist as a separate entity. This matters because the operational and legal consolidation is not treated as completed simply because the NCLT has sanctioned the scheme.

In practical terms, the period between the NCLT order and the RoC filing is when companies complete statutory steps, coordinate filings, and ensure all scheme conditions are met. Only after that will the dissolution of QCIL (without winding up) and the merged structure become operative.

Shareholder and creditor approvals: 96.68% vote in favour

Separate disclosures included a key internal milestone: 96.68% shareholder approval for the merger with QCIL. The company commentary also referenced shareholder and creditor approvals, with 96.7% of shareholder votes cast in favour.

The approvals were presented as evidence of alignment on the transaction’s strategic rationale and structure. These votes follow earlier regulatory steps and are part of the required process before the NCLT issues its sanction. With the NCLT order now received, the transaction has moved into the final statutory-completion phase.

Regulatory trail: CCI approval and stock exchange no-objection

The material also referenced prior approvals that preceded NCLT sanction. It states the proposed merger received Competition Commission of India (CCI) approval and “no objection” letters from stock exchanges.

One specific disclosure notes that the CCI, in its meeting held on 15 April 2025, approved the proposed merger under Section 31(1) of the Competition Act, 2002. Another process detail referenced in the timeline is that the merger application was filed with the NCLT on 11 December 2025.

Scale of the combined platform: beds, hospitals, footprint

The combined entity has been described as a large hospital platform with metrics cited across different disclosures. One update referred to a “mega hospital network” of over 10,600 beds, with a pipeline expected to exceed 15,500 beds in the near term. Another description put the network at 39 hospitals with over 10,625 beds, across nine states and 28 cities, and supported by more than 36,307 employees and clinicians.

Other references in the same material included slightly different bed counts, such as 10,150+ beds across 27 cities and 10,500 bed-capacity across 27 states, alongside a description positioning the combined entity among the top three hospital chains in India. These figures appear as part of multiple public descriptions of the transaction’s scale.

Corporate actions already completed: 5% stake acquisition via share swap

Before the full amalgamation, Aster DM Healthcare also disclosed a transaction involving QCIL equity. It acquired a 5% stake in Quality Care India Ltd from Blackstone Capital Partners (BCP) and Centella via a share swap. The transaction involved acquiring 1,90,46,028 QCIL equity shares for a value of ₹849.13 crore.

In exchange, Aster DM allotted 1,86,07,969 equity shares (face value ₹10 each) to BCP and Centella. The disclosures framed this step as being undertaken ahead of the planned merger announced in November 2024.

Timelines mentioned: next quarter and Q1 FY27 integration

Several timeline references were included across the material. One statement said the combined entity is on track to complete integration in Q1 FY27. Another description said the merger was anticipated to finalize within the next quarter, subject to remaining formalities.

Aster’s deputy managing director Alisha Moopen was also cited as telling Mint that the merger is expected to be completed in the first quarter of fiscal 2027. In earlier process guidance, the company had said it expected to complete the merger by Q1 of FY2026-27, subject to receipt of remaining regulatory approvals and fulfilment of customary conditions.

Key facts at a glance

Market impact: what investors should watch now

The immediate market relevance is procedural and event-driven rather than financial-result driven. The NCLT order indicates the merger has crossed a major legal checkpoint, but the transaction is not complete until the RoC filing occurs and all scheme conditions are met. Because the scheme is not effective yet, the corporate existence of QCIL remains unchanged for now.

For investors, the next identifiable trigger mentioned in the disclosures is the company’s announcement confirming filing of the NCLT order with the Registrar of Companies. That filing is expected to mark completion, after which QCIL will be dissolved without winding up and Aster DM will announce the effective date to stock exchanges. Separately, investors may also track how the company communicates integration timelines such as Q1 FY27, since that has been referenced as a target period for completing integration.

Conclusion

Aster DM Healthcare’s receipt of the NCLT Hyderabad order sanctioning QCIL’s amalgamation is a decisive step in the merger process, but the scheme will take effect only after RoC filing and other conditions are fulfilled. Until then, QCIL remains a separate entity. The next update to watch is the company’s exchange announcement confirming the RoC filing and the effective date, which would complete the amalgamation and trigger QCIL’s dissolution without winding up.